跳至主要内容
临床试验/NCT05361902
NCT05361902进行中(未招募)不适用

A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer: a Prospective Safety and Feasibility Study in Patients With Metastatic Prostate Cancer

Erasmus Medical Center2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2022年7月7日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
35
试验地点
2
主要终点
Feasibility of margin reduction expressed as percentage of underdosage at the seminal vesicles

研究概览

简要总结

This study aims to make a first step towards ultra-hypofractionation for high-risk prostate cancer by proving the technical feasibility of margin reduction of the seminal vesicles by combining the intra-fraction fiducial tracking with an online re-planning workflow for each fraction to account for the inter-fraction seminal vesicle motion.

详细描述

Rationale:

One of the key treatment modalities for prostate cancer is external beam radiation therapy. Considering the relatively low alpha/beta ratio of prostate cancer, increasing the dose per fraction could yield higher tumour control rates with acceptable toxicity in a reduced number of treatment fractions (hypofractionation). Ultrahypofractionation (fraction dose > 5 Gy) has shown promising results for low- and intermediate risk prostate cancer.

Ultrahypofractionation for high-risk prostate cancer however is challenging as the seminal vesicles (SV) are included in the target volume, which is not the case for intermediate and low-risk prostate cancer patient. These SV belong to the male reproduction system and their exact shape and size can differ substantially. The SV are attached bilaterally to the prostate and, similarly to the prostate, their motion is caused by changes in bladder and rectal filling status. However, although the cause of motion is similar for both the prostate and the SV, multiple studies report that the inter- and intra-fraction motion of the SV remain significant and largely uncorrelated to the prostate motion.

Considering the SV must be included in the target volume, the significant SV motion has to be accounted for during treatment. A solution is to use safety margins to extend the clinical target volume (CTV) to the planning target volume (PTV). Due to their substantial inter- and intra-fraction motion, the SV require a relatively large PTV-margin of 8 mm, which causes the bladder and rectum to receive more dose per fraction, which in combination with a higher fraction dose could result in unacceptable genitourinary and gastrointestinal toxicity rates.

This means that to safely introduce ultra-hypofractionation for high-risk prostate cancer patients, strategies to minimize PTV-margins around the SV are required. To account for the inter-fraction motion of the SV, adaptive radiotherapy (ART) in the form of online re-planning could be the solution. Online re-planning is a workflow in which a new treatment plan is generated for each fraction, optimized on the anatomy of the day. ART accounting for the intra-fraction motion of the prostate has been studied well, for example by tracking the intra-prostatic markers with the CyberKnife system. Using the in-room Computed Tomography (CT) scan of our institution's CyberKnife, it is feasible to combine online re-planning with intra-fraction fiducial tracking.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Histologically proven prostate cancer
  • Radiologically proven limited metastatic disease
  • Referred to the Erasmus MC, after multidisciplinary consensus, for local radiotherapy treatment similar to the STAMPEDE trial
  • Willing to and capable of personally filling out online questionnaire
  • Signed written informed consent

排除标准

  • Previous pelvic radiotherapy or surgery for prostate cancer (excluding surgery to improve urinary function in benign prostate hyperplasia, i.e. trans-urethral resection of the prostate or prostatectomy according to Millin or Hryntschak)
  • According to current clinical protocols at discretion of the treating physician, patients can be excluded in case of, for example, an International Prostate Symptom Score of >20 or a prostate volume of >90 milliliters, expecting an unacceptable rise in toxicity rates

结局指标

主要结局

Feasibility of margin reduction expressed as percentage of underdosage at the seminal vesicles

时间窗: 17 months

Percentage of patients for which in 0 or 1 fraction out 6 fractions the seminal vesicles were underdosed. Underdosage being defined as 95% of the volume of SV receiving \< 95% of prescribed dose. In the case of unavoidable underdosage of the target on the reference plan, coverage below the achieved coverage in the reference plan will be seen as an underdosed fraction. The margin reduction of the SV is considered feasible when ≥90% of patients received successful treatments.

次要结局

  • Acute toxicity (CTCAE)(20 months)
  • Late toxicity (CTCAE)(4 years)
  • Acute toxicity (RTOG/EORTC)(20 months)
  • Late toxicity (RTOG/EORTC)(4 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Luca Incrocci, MD PhD

Luca Incrocci, MD PhD, Professor of Genito-Urinary Radiotherapy

Erasmus Medical Center

研究点 (2)

Loading locations...

相似试验

A First Step Towards Ultra-hypofractionation for... | 临床试验